What is HC Wainwright’s Estimate for ImageneBio Q3 Earnings?

ImageneBio, Inc. (NASDAQ:IMA) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of ImageneBio in a research note issued on Friday, August 21st. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.98) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.07) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.57) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.28) EPS, Q3 2027 earnings at ($1.44) EPS, Q4 2027 earnings at ($1.62) EPS, FY2027 earnings at ($5.48) EPS, FY2028 earnings at ($5.07) EPS, FY2029 earnings at ($4.73) EPS and FY2030 earnings at ($4.61) EPS.

ImageneBio (NASDAQ:IMA) last released its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.27.

IMA has been the topic of a number of other reports. Wall Street Zen downgraded shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. Wedbush restated an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $29.00.

ImageneBio Stock Up 2.0%

IMA stock opened at $5.62 on Tuesday. ImageneBio has a 52 week low of $3.94 and a 52 week high of $14.34. The business has a 50-day simple moving average of $5.79 and a 200 day simple moving average of $5.85. The company has a market cap of $63.79 million, a PE ratio of -1.23 and a beta of 0.76.

Hedge Funds Weigh In On ImageneBio

A number of institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC bought a new stake in shares of ImageneBio during the 2nd quarter worth $539,044,000. Trails Edge Capital Partners LP acquired a new stake in ImageneBio in the second quarter valued at about $1,663,824,000. Hsbc Holdings PLC bought a new position in ImageneBio in the second quarter valued at about $208,000. Cable Car Capital LP bought a new position in ImageneBio in the second quarter valued at about $4,611,000. Finally, Blue Owl Capital Holdings LP bought a new position in ImageneBio in the second quarter valued at about $5,414,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Key ImageneBio News

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage on ImageneBio with a Buy rating and a $28.00 price target, substantially above the stock’s recent trading level. The bullish rating and large implied upside provide the main positive catalyst for IMA shares. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: The analyst’s current-year loss estimate of $3.07 per share is less pessimistic than HC Wainwright’s separate FY2026 estimate of a $3.57-per-share loss, suggesting expectations may improve over the near term. The company also recently exceeded quarterly EPS expectations, providing additional support for investor sentiment.
• Neutral Sentiment: HC Wainwright projects losses of $0.98 per share in Q3 2026 and $1.02 in Q4 2026, followed by quarterly losses of $1.14, $1.28, $1.44 and $1.62 through Q4 2027. The firm forecasts full-year losses of $5.48 in FY2027, $5.07 in FY2028, $4.73 in FY2029 and $4.61 in FY2030, underscoring that the investment case depends on future clinical or commercial progress rather than near-term profitability.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.